Good MorningEquities pulled back a little at the end of the last week of 2021 but left the S&P 500 trading at a new all-time for the year. The move caps off another year of outsized gains for the index, gains that were driven in large part by stimulus spending and inflation. With stimulus spending a thing of the past and inflation still a concern there is a risk earnings growth will come to a standstill in 2022.
The biggest news this week will come from the economic front and includes the FOMC minutes as well as the monthly NFP reading. The minutes will be important for clues to the FOMC’s plans on rate hikes while the NFP data will tell us how many new jobs were created in December. Also on tap this week are readings on ISM, PMI, construction spending, and factory orders so there will be plenty for the market to chew on.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Finance | |
Take the guesswork out of investing in volatile stocks by looking at stocks with a high upside
Traders love high-volatility stocks because they have the potential to quickly make large price swings. Being on the right side of those trades sets them up for quick profits. But that doesn’t me... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | |
You can't say you've never heard of a contrarian viewpoint if you've never heard or read Warren Buffett's famous quote, "Be fearful when others are greedy and greedy when others are fearful."
Contrarian investing is just that — it means investing against the crowd. But it's a hard way to go... Read the Full Story |
|
Technology | | Investors and traders always want an edge as the calendar flips over to a new year, and Innovative Industrial Properties (NYSE: IIPR), Zscaler (NASDAQ: ZS) and Axcelis Technologies (NASDAQ: ACLS) are showing signs of technical and fundamental strength that could lead to further gains.
A little con... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Materials | |
Cyclical Stocks Could Be in for a Strong Year Ahead
The economy moves in waves, and it’s always important for investors to recognize its current stage of the business cycle in order to make smarter strategic moves. Periods of expansion, contraction, troughs, peaks, and recovery all have dif... Read the Full Story |
|
Markets | |
These stocks disappointed investors but still have trends on their side
There’s no doubt that growth investors have not been disappointed with the market performance over the last two years. Even a bear market in the early part of 2021 didn’t last long. And that was good news for man... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | | After growing steadily for the better part of the last decade, the e-commerce space truly came of age last year during the Covid-19 pandemic. With physical stores shut and much of the population urged to stay at home, disposable income increased and the only outlet was via online shopping. If we tak... Read the Full Story |
|
Consumer Discretionary | |
Tractor Supply Company Is A Buy Ahead Of Earnings
Stay-at-home and lifestyle stocks like Tractor Supply Company (NASDAQ: TSCO) are among the biggest winners of the pandemic. The pandemic was a game-changing event for the company that amplified sales just as a new CEO and his well-timed plans wer... Read the Full Story |
|
Consumer Discretionary | |
These Blue Chips Are Moving Higher On Analyst Support
Blue-chip stocks like McDonald’s (NYSE: MCD) and Cintas (NASDAQ: CTAS) may not have the flash and bang of their growth-oriented counterparts but there are other things to like about them. Both companies are growing despite their large s... Read the Full Story |
|
Energy | |
There are no sure things in investing, but these three sectors have strong catalysts to fuel their growth
If you had GameStop (NYSE: GME) on your bingo card of stocks that would outperform the market in 2021, you probably won’t get much from this article. However, as 2021 showed us; there&... Read the Full Story |
|
Consumer Discretionary | |
According to Merriam-Webster, New Year’s resolutions may have been around since the late 17th century. Scottish writer Anne Halkett’s January 2, 1671, diary entry titled “Resolutions” listing several pledges suggests people have engaged in the tradition for some 350 years.
... Read the Full Story |
|
The Early Bird Stock Of The Day Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. | | View Today's Stock Pick |
|
